Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000926617-26-000020
Filing Date
2026-04-01
Accepted
2026-04-01 15:46:13
Documents
82
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K awhl-20251231x10k.htm   iXBRL 10-K 2349083
2 EX-23.1 awhl-20251231xex23d1.htm EX-23.1 4208
3 EX-31.1 awhl-20251231xex31d1.htm EX-31.1 12330
4 EX-31.2 awhl-20251231xex31d2.htm EX-31.2 12314
5 EX-32.1 awhl-20251231xex32d1.htm EX-32.1 10280
  Complete submission text file 0000926617-26-000020.txt   10753974

Data Files

Seq Description Document Type Size
6 EX-101.SCH awhl-20251231.xsd EX-101.SCH 73568
7 EX-101.CAL awhl-20251231_cal.xml EX-101.CAL 67462
8 EX-101.DEF awhl-20251231_def.xml EX-101.DEF 303443
9 EX-101.LAB awhl-20251231_lab.xml EX-101.LAB 701910
10 EX-101.PRE awhl-20251231_pre.xml EX-101.PRE 490827
86 EXTRACTED XBRL INSTANCE DOCUMENT awhl-20251231x10k_htm.xml XML 1757456
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34810 | Film No.: 26827903
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)